Wednesday, May 6, 2026
← Back to archivePolicy
Policy•STAT News•May 6, 2026
Opinion: Trump’s executive order on psychedelics is the right move. But is my field ready for it?
background ▾
- •The executive order does not lower FDA evidence standards but removes institutional inertia that has constrained psychedelic drug development; priority review vouchers and accelerated scheduling are already being deployed.
- •The Lykos MDMA/PTSD rejection in 2024 exposed critical trial design failures (unblinding, unstandardized therapy, durability questions) that the field must address under new FDA guidance issued in 2023.
- •The critical bottleneck going forward is not regulatory but operational: closing the 'know-do gap' between what trials show is possible and what the healthcare system can deliver, particularly the shortage of trained clinician-therapists required for intensive psychedelic-assisted therapy protocols.
Compass PathwaysUsona InstituteOtsukapsilocybinMDMAmethylone
→ Read original articlePolicy•KFF•May 6, 2026
MAHA Health Concerns Resonate Broadly but Lag Behind Health Care Costs Even for MAHA Voters
background ▾
- •Healthcare cost reduction outweighs MAHA signature issues (food safety, vaccines) as the primary health priority for voters, including MAHA supporters themselves—a critical finding for policy prioritization
- •Only 32% of MAHA voters strongly approve of HHS Secretary Kennedy's job performance despite the movement being aligned with his agenda, suggesting limited enthusiasm or concern about implementation effectiveness
Policy•KFF•May 6, 2026
KFF Health Tracking Poll: MAHA and the Midterms
background ▾
- •MAHA enjoys 40% public support but is heavily partisan (two-thirds Republican), indicating significant political polarization around RFK Jr.'s health agenda and potential regulatory changes affecting pharma/biotech.
- •Broad bipartisan consensus exists on stricter food additive and pesticide regulation (75% and 64% respectively), signaling likely regulatory tightening that could impact drug formulations, excipients, and agricultural chemical approvals.
- •Healthcare costs remain the dominant public health concern even among MAHA voters (outpacing movement-specific issues), suggesting that drug pricing, reimbursement, and access remain central political battlegrounds regardless of MAHA's public health messaging focus.
Policy•Fierce Pharma•May 6, 2026
Novartis to close German manufacturing site, cutting 220 jobs
background ▾
- •Novartis is closing its Wehr, Germany manufacturing site by 2028, cutting 220 jobs as part of ongoing operational restructuring
- •This is part of a multiyear company-wide overhaul, suggesting broader manufacturing footprint optimization across Novartis
Novartis
→ Read original articlePolicy•STAT News•May 6, 2026
Opinion: Dr. Glaucomflecken wants to make a stink
background ▾
- •This is an opinion/interview piece with no substantive pharma or healthcare policy news—it is a profile of a healthcare advocate rather than a news story with industry impact
Market Access
Market Access•Fierce Pharma•May 6, 2026
Newly formed Keenova launches ‘Don't Be a Viking’ campaign for Dupuytren’s contracture
background ▾
- •Keenova is operationalizing its post-merger integration through DTC marketing for an established indication
KeenovaMallinckrodtEndo
→ Read original articleMarket Access•Fierce Biotech•May 5, 2026
After Arcellx buyout close, Gilead trims 108 jobs at CAR-T biotech's Redwood City outpost
background ▾
- •Gilead has closed the $7.8 billion Arcellx acquisition and is immediately consolidating ~52% of Arcellx's Redwood City workforce (108 of 209 employees), typical post-acquisition integration behavior.
- •Anito-cel FDA decision expected by December 23, 2026; commercial success hinges on reaching $6 billion cumulative sales by 2029 to unlock full earn-out value.
- •Monitor FDA approval timing and anito-cel launch execution in fourth-line multiple myeloma to validate the acquisition thesis and earn-out probability.
Gilead SciencesArcellxKite Pharmaanito-celanitocabtagene autoleucel
→ Read original articleMarket Access•Fierce Biotech•May 5, 2026
Olympus, EndoRobotics in distribution pact for robot-assisted endoscopic tech
background ▾
- •Olympus gains access to robot-assisted endoscopic technology through EndoRobotics partnership, complementing its existing GI robotics initiatives (Revival Healthcare JV, AI polyp detection, Gore distribution deal)
- •Strategic focus on ESD adoption and early GI cancer treatment aligns with Olympus' stated goal to expand endoscopic procedure access, particularly in underserved geographies
OlympusEndoRoboticsW.L. GoreGore Viabil
→ Read original articleMarket Access•Endpoints News•May 5, 2026
Pfizer's Albert Bourla says he has no mega-merger plans
background ▾
- •Pfizer leadership is signaling no transformative M&A deals are planned for the near future, suggesting the company will focus on organic growth and existing pipeline
Pfizer
→ Read original articleMarket Access•Fierce Pharma•May 6, 2026
Pfizer delivers strong Q1 but keeps guidance steady amid COVID seasonality
background ▾
- •Pfizer beat Q1 expectations but chose not to raise full-year guidance, signaling management caution despite operational performance
PfizerCOVID-19 vaccines
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•May 6, 2026
Avalo’s phase 2 skin disease win fuels pursuit of AbbVie despite placebo headwind
background ▾
- •Abdakibart achieved statistically significant HiSCR75 response but at 16.9% placebo-adjusted rate fell below Avalo's 20% internal target and company guidance of 'clear win' threshold
- •Unusually high placebo response rate (25.6%) limited the apparent drug effect; this mirrors challenges seen in MoonLake's Vela-2 HS trial and may reflect underlying trial design or patient population factors
- •Watch phase 3 data and head-to-head competitive positioning versus AbbVie's lutikizumab, which showed 21% placebo-adjusted response; regulatory pathway and payer reception will depend on phase 3 outcomes in this crowded inflammatory disease space
Avalo TherapeuticsAbbVieMoonLake Immunotherapeuticsabdakibartlutikizumab
→ Read original articleClinical Trials•Fierce Biotech•May 5, 2026
Pfizer’s $2.3B Trillium bet ends in failure as remaining CD47 blocker scrapped along with T-cell engager
background ▾
- •Pfizer's entire $2.3B Trillium acquisition has yielded zero approved drugs, with both lead CD47 inhibitors (ontorpacept and maplirpacept) now discontinued, representing a major strategic failure in oncology M&A.
- •CD47 inhibition continues to be a clinically validated but commercially failed modality across the industry—neither Pfizer's maplirpacept nor Gilead's magrolimab have succeeded despite substantial investment, suggesting fundamental translational challenges.
- •Watch for: (1) whether Pfizer re-enters T-cell engager space or continues to retreat from this hot modality; (2) industry reassessment of CD47 biology and target validation; (3) whether remaining CD47 programs (e.g., from other sponsors) face similar recruitment or efficacy headwinds.
PfizerTrillium TherapeuticsIncytemaplirpaceptontorpaceptMonjuvi
→ Read original articleClinical Trials•Fierce Biotech•May 5, 2026
Viridian’s Tepezza rival racks up second phase 3 win, clearing path to FDA
background ▾
- •Elegrobart achieved statistically significant proptosis reduction in chronic TED patients (50-54% response rate at Week 24 vs. 15% placebo), clearing the path to FDA filing in Q1 2025 and establishing a second positive Phase 3 trial.
- •Tepezza appears to maintain an efficacy edge based on indirect comparisons—Amgen's Phase 4 data showed 62% response in chronic TED vs. elegrobart's 50-54%—but Viridian's lower dosing frequency (every 4-8 weeks vs. every 3 weeks) and subcutaneous administration may differentiate on convenience.
- •Watch for Q1 2025 FDA filing outcome and the competitive landscape shift when Amgen's subcutaneous Tepezza formulation launches, as well as the June 30 FDA decision on Viridian's IV candidate veligrotug, which could fragment Viridian's own market opportunity.
Viridian TherapeuticsAmgenHorizon TherapeuticselegrobartTepezzaveligrotug
→ Read original articleClinical Trials•Fierce Pharma•May 6, 2026
Cytokinetics' Myqorzo succeeds in landmark cardiomyopathy trial
background ▾
- •Myqorzo demonstrated efficacy in phase 3 HCM trial, with potential to become the first approved treatment in non-obstructive HCM
- •First-in-class positioning could provide substantial competitive advantage and market exclusivity in an unmet medical need
- •Watch for regulatory submission timeline and FDA decision; commercial success will depend on reimbursement and pricing in a rare disease indication
CytokineticsMyqorzoomecamtiv mecarbil
→ Read original articleClinical Trials•Fierce Biotech•May 6, 2026
J&J’s Ottava surgical robot meets primary endpoints in gastric bypass study
background ▾
- •Ottava achieved 100% robotic completion rate in 30-patient gastric bypass study with all primary safety and performance endpoints met at 30 days post-procedure
- •De novo FDA application filed; approval would establish new regulatory pathway for compact surgical robots designed for space-constrained operating rooms
- •Watch for FDA de novo decision timeline and potential market adoption data; competitive intensity in robotic surgery increasing with multiple new platforms entering market
Johnson & JohnsonIntuitive SurgicalMedtronicOttava
→ Read original article